Results · Apr-Jun 2026
Concord Biotech Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 26% to ₹257 crore from ₹204 crore in Apr-Jun 2025.
Operating profit grew 34% to ₹82.4 crore, an operating margin of 32.0% (up 1.9 points from a year ago).
Net profit grew 31% to ₹57.7 crore from ₹44.1 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −21%, net profit −35%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 257.5 | 204.0 | +26% |
| Operating profit (EBITDA) | 82.4 | 61.4 | +34% |
| Operating margin | 32.0% | 30.1% | +1.9 pts |
| Net profit | 57.7 | 44.1 | +31% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.